好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Within-Person Consistency of Acute Treatment Success With Ubrogepant: Results From a Long-term Safety Study
Headache
P2 - Poster Session 2 (11:45 AM-12:45 PM)
15-003
To evaluate within-person consistency of treatment benefits with ubrogepant.
Because people with migraine treat multiple attacks, consistency of treatment benefit is important; however, it has been evaluated in a number of different methodologies and most commonly, as consistency of 2-hour pain relief (2hrPR). The estimated consistency for 2hPR with ubrogepant treatment (pooled doses) has been shown to be 68.6%, with 31.0% of participants achieving 2hPR for 2 out of 3 (2/3) and 37.6% achieving 2hPR for 3 out of 3 (3/3) attacks.1
Data from a phase 3, multicenter, randomized, 52-week, open-label trial of adults with migraine were analyzed by pooling participants who were treated with ubrogepant 50mg or 100mg. For this analysis, eligible participants treated at least 3 migraine attacks of moderate/severe pain intensity during the first 3 months of the trial. Consistency was defined as the proportion of participants who treated attacks of moderate or severe pain and achieved 2-hour treatment success (2hTS) in 2/3 or 3/3 attacks. Previous research identified this novel approach using latent class modeling (LCM) to identify 2-hour treatment success (2hTS).2 The LCM approach used 5 efficacy measures to define treatment success: pain intensity, functional disability, and presence of nausea, photophobia, and phonophobia. To align with previous research, item-weights that were previously estimated via LCM were used to classify participants as treatment success or failure.

Based on data from the first 3 attacks in 490 eligible participants, the estimated consistency for 2hTS, was 55.9%, with 27.3% of participants achieving 2hTS for 2/3 attacks and 28.6% achieving 2hTS for 3/3 attacks. 

Based on LCM of 2hTS, ubrogepant delivers high rates of within-person consistency in treatment responses.

References:

1. Data on file, AbbVie Inc.

2. Lipton RB, et al. Neurology. 2021;96(15 suppl):1528.

 
Authors/Disclosures
Aubrey Adams, PhD
PRESENTER 		Dr. Manack Adams has received personal compensation for serving as an employee of Abbvie. Dr. Manack Adams has stock in Abbvie.
Charles Iaconangelo, PhD (Pharmerit) Dr. Iaconangelo has received personal compensation for serving as an employee of Open Health Group.
No disclosure on file
No disclosure on file
Janette Contreras-De Lama Janette Contreras-De Lama has received personal compensation for serving as an employee of AbbVie. Janette Contreras-De Lama has stock in AbbVie.
Joel M. Trugman, MD, FAAN Dr. Trugman has received personal compensation for serving as an employee of AbbVie. Dr. Trugman has stock in AbbVie.
Richard B. Lipton, MD, FAAN (Albert Einstein College of Medicine) Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clexio. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has or had stock in Biohaven.Dr. Lipton has or had stock in Manistee.Dr. Lipton has or had stock in Axon.Dr. Lipton has or had stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.